BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25607660)

  • 1. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
    Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
    PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Fukushima N; Maitra A; Iacobuzio-Donahue CA; van Heek NT; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Am J Pathol; 2004 Mar; 164(3):903-14. PubMed ID: 14982844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated expression level of microRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas.
    Aso T; Ohtsuka T; Tamura K; Ideno N; Kono H; Nagayoshi Y; Ohuchida K; Ueda J; Takahata S; Shindo K; Aishima S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Apr; 43(3):361-6. PubMed ID: 24622064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X; Yu C; Li J; Yu S; Chen J
    Int J Med Sci; 2017; 14(5):412-418. PubMed ID: 28539816
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
    Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
    Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas.
    Hong SM; Omura N; Vincent A; Li A; Knight S; Yu J; Hruban RH; Goggins M
    Clin Cancer Res; 2012 Feb; 18(3):700-12. PubMed ID: 22173550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
    Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms.
    Caponi S; Funel N; Frampton AE; Mosca F; Santarpia L; Van der Velde AG; Jiao LR; De Lio N; Falcone A; Kazemier G; Meijer GA; Verheul HM; Vasile E; Peters GJ; Boggi U; Giovannetti E
    Ann Oncol; 2013 Mar; 24(3):734-41. PubMed ID: 23139258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
    Sato N; Matsubayashi H; Abe T; Fukushima N; Goggins M
    Clin Cancer Res; 2005 Jul; 11(13):4681-8. PubMed ID: 16000561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatic Analysis and Integration of Transcriptome and Proteome Results Identify Key Coding and Noncoding Genes Predicting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Saha B; Chhatriya B; Pramanick S; Goswami S
    Biomed Res Int; 2021; 2021():1056622. PubMed ID: 34790815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Ueki T; Fukushima N; Iacobuzio-Donahue CA; Yeo CJ; Cameron JL; Hruban RH; Goggins M
    Gastroenterology; 2002 Jul; 123(1):365-72. PubMed ID: 12105864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.
    Omori Y; Ono Y; Tanino M; Karasaki H; Yamaguchi H; Furukawa T; Enomoto K; Ueda J; Sumi A; Katayama J; Muraki M; Taniue K; Takahashi K; Ambo Y; Shinohara T; Nishihara H; Sasajima J; Maguchi H; Mizukami Y; Okumura T; Tanaka S
    Gastroenterology; 2019 Feb; 156(3):647-661.e2. PubMed ID: 30342036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing.
    Kuratomi N; Takano S; Fukasawa M; Maekawa S; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Takada H; Nakakuki N; Kato R; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Inoue T; Kondo T; Ichikawa D; Enomoto N
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms.
    Permuth JB; Choi J; Balarunathan Y; Kim J; Chen DT; Chen L; Orcutt S; Doepker MP; Gage K; Zhang G; Latifi K; Hoffe S; Jiang K; Coppola D; Centeno BA; Magliocco A; Li Q; Trevino J; Merchant N; Gillies R; Malafa M;
    Oncotarget; 2016 Dec; 7(52):85785-85797. PubMed ID: 27589689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
    Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
    Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.